Previous 10 | Next 10 |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 18, 2024) - Faruqi & Faruqi, LLP, a leading national ...
Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a confer...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 12, 2024) - Faruqi & Faruqi, LLP, a leading national ...
2024-05-10 14:13:46 ET More on Alphabet, Recursion, etc. Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript Bronte Capital - Alphabet: Could Not Find Anything We Liked More Google: The Recent Surge Is Far From Over CrowdStrike, Google exp...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 7, 2024) - Faruqi & Faruqi, LLP, a leading national s...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 25, 2024 in Exscientia plc Lawsuit - EXAI Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 25, 2024 in Exscientia plc Lawsuit - EXAI PR Newswire NEW YORK , ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 5, 2024) - Faruqi & Faruqi, LLP, a leading national s...
2024-05-02 13:05:00 ET Summary The AI ecosystem comprises semiconductors, software, other hardware and innovative use cases, all of which play crucial roles in the advancement and adoption of AI. Realistic expectations for 2024 include the potential for a hardware refresh cycle dr...
2024-04-24 17:41:05 ET Gainers: Acrivon Therapeutics ( ACRV ) +19% . Impinj ( PI ) +10% . Exscientia ( EXAI ) +6% . Churchill Downs ( CHDN ) +5% . PowerFleet ( PWFL ) +5% . Losers: Meta Platforms ( META ) ...
2024-04-24 09:19:50 ET More on Moderna Moderna Investors Should Beware Patent-Dispute Fallout Moderna: Considering The Cancer Vaccine Angle Moderna Continues To Build A Pipeline S&P 500 stocks with biggest estimated EPS declines for Q1 Moderna sto...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...